<DOC>
	<DOC>NCT00730964</DOC>
	<brief_summary>This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.</brief_summary>
	<brief_title>A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.</brief_title>
	<detailed_description />
	<criteria>The subject is over 18 years old. The subject has been scheduled for an Optisonenhanced echocardiography exam. The subject has provided signed and dated informed consent. Known hypersensitivity to perflutren, blood, blood products or albumin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Surveillance</keyword>
	<keyword>Optison</keyword>
	<keyword>Perflutren</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Subjects receive Optison during enhanced echocardiography</keyword>
</DOC>